PomDoctor announced that it has commenced to terminate its American Depositary Receipt program, including the termination of the related deposit agreement, as amended, and list the Company's Class A ordinary shares directly on The Nasdaq Stock Market. The termination was previously approved by the board of directors of Pomdoctor on September 3, 2026 and approved by the company's shareholders on a non-binding advisory basis at the extraordinary general meeting of shareholders held on September 30, 2026. The ADR Program to be terminated was established pursuant to the Deposit Agreement, dated October 9, 2025, as amended, among the company, Citibank, N.A. and the holders and beneficial owners of the American Depositary Shares issued thereunder. The ADR Program and the Deposit Agreement are expected to terminate prior to the opening of the market on October 21, 2026. At that time, the company's ADSs will be mandatorily cancelled and exchanged for the Class A ordinary shares to be distributed to the ADS holders according to the Deposit Agreement. Simultaneously with the effectiveness of the termination of the ADR Program, the company will effect a share consolidation of its Class A ordinary shares and Class B ordinary shares, pursuant to which every ten ordinary shares of each class will be consolidated into one ordinary share of the same class. As a result of the Share Consolidation and Mandatory Exchange, each holder of ten (10) ADSs will receive three (3) post-Share Consolidation Class A ordinary shares. In connection with the termination of the ADR Program and Share Consolidation, the company plans to list its Class A ordinary shares for trading on Nasdaq in substitution for the ADSs. The company's Class A ordinary shares are expected to commence trading on Nasdaq when the market opens on October 21, 2026 under the symbol "POM" with the new CUSIP number G7166T112.

10/9 16:30

PomDoctor Receives Compliance Notice from Nasdaq

PomDoctor announced that it received a staff determination letter from Nasdaq on October 6. The letter notified the company that the closing bid price of the company's American depositary shares had been below $1.00 per share for 30 consecutive business days, from August 24, through October 5. As a result, the company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450.

7/9 08:30

PomDoctor Advances AI Chronic Disease Management Ecosystem

PomDoctor highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence, remote patient monitoring, wearable technologies and real-world healthcare data to evolve toward a predictive, continuous and personalized healthcare service provider. Zhenyang Shi, Chairman and Chief Executive Officer of PomDoctor, commented: "The healthcare industry is entering a new era where AI, continuous health data and connected technologies are accelerating the transformation of chronic disease management. With increasing demand for proactive healthcare solutions, we believe AI-powered predictive capabilities and remote monitoring technologies will play an increasingly important role in improving long-term health management

2/2 06:10

PomDoctor Receives Nasdaq Deficiency Notice

PomDoctor announced that it has received a written notification from the staff of Nasdaq dated January 29, indicating that for the last 33 consecutive business days, the closing bid price of the company's American depositary shares was below the minimum bid price of $1.00 per share requirement set forth in Nasdaq Listing Rule 5450. The Deficiency Letter has no current effect on the listing or trading of the company's ADSs on Nasdaq. Pursuant to Nasdaq Listing Rule 5810, the company is provided with a compliance period of 180 calendar days, or until July 28, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the compliance period, the closing bid price of the company's ADSs is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the company a written confirmation of compliance and the matter will be closed. In the event the company does not regain compliance by July 28, subject to the determination by the staff of Nasdaq, the company may be eligible for additional time. The deficiency letter will have no effect on the company's business operations, and the company will take all reasonable measures to regain compliance.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。